Global AI In Precision Medicine Market Strategic Research Report

The global AI in precision medicine Market Strategic Research Report">precision medicine market has emerged as one of the most consequential intersections of computational science and clinical care, valued at approximately USD 3.2 billion in 2024. Precision medicine—the practice of tailoring therapeutic decisions to the individual patient's genetic, phenotypic, and environmental profile—has historically been constrained by the sheer analytical complexity of multi-omic data sets. Artificial intelligence, encompassing machine learning, deep learning, and natural language processing, addresses this constraint directly by identifying patterns across data volumes that no human analyst could process within clinically actionable timeframes. The market spans applications from genomic variant interpretation and drug-target identification to clinical trial patient stratification and real-time therapeutic response prediction, making it a foundational layer in the future architecture of personalized healthcare delivery across oncology, rare diseases, cardiology, and neurological disorders.

Growth in this market is propelled by three converging forces of exceptional commercial weight. First, the precipitous decline in whole-genome sequencing costs—from roughly USD 1,000 per genome in 2015 to under USD 200 in 2024—has dramatically increased the volume of genomic data requiring intelligent interpretation, creating a structural demand for AI-driven analytics pipelines. Second, pharmaceutical companies face unsustainable attrition rates in late-stage clinical trials, with failure rates exceeding 90% in oncology; AI-assisted patient stratification and biomarker discovery are demonstrably reducing these failure rates, generating a clear return-on-investment case for enterprise adoption. Third, regulatory momentum has accelerated, with the U.S. FDA issuing guidance frameworks for AI/ML-based software as a medical device (SaMD), reducing the commercial uncertainty that previously dampened institutional investment. The primary restraint remains data fragmentation across incompatible electronic health record systems and the absence of unified global data-sharing frameworks, which constrains the training data available for model development.

This report delivers a comprehensive, commercially precise analysis of the global AI in precision medicine market covering the period 2019 through 2032, with a base year of 2024. It segments the market by technology type, application, and end user, and provides country-level forecasts across six major geographies. Corporate strategy teams, investment analysts, M&A advisors, and procurement managers seeking to evaluate competitive positioning, identify acquisition targets, or benchmark technology adoption trajectories will find this report an indispensable analytical resource.